Therapeutic Area: Oncology

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Fraietta et al.
Nature
Papers
May 2018
immuneAccess
Authors and Affiliates
Joseph A. Fraietta1,2,3,4, Christopher L. Nobles5, Morgan A. Sammons6,10, Stefan Lundh1,2, Shannon A. Carty2,11, Tyler J. Reich1,2, Alexandria P. Cogdill1,2, Jennifer J. D. Morrissette3, Jamie E. DeNizio7,8, Shantan Reddy5, Young Hwang5, Mercy Gohil1,2,Irina Kulikovskaya1,2, Farzana Nazimuddin1,2, Minnal Gupta1,2, Fang Chen1,2, John K. Everett5, Katherine A. Alexander6, Enrique Lin-Shiao6, Marvin H. Gee9, Xiaojun Liu1,2, Regina M. Young1,2, David Ambrose1,2, Yan Wang1,2, Jun Xu1,2, Martha S. Jordan2,3, Katherine T. Marcucci1,2, Bruce L. Levine1,2,3, K. Christopher Garcia9, Yangbing Zhao1,2, Michael Kalos1,2,3, David L. Porter1,2,7, Rahul M. Kohli5,7,8, Simon F. Lacey1,2,3, Shelley L. Berger6, Frederic D. Bushman5, Carl H. June1,2,3,4 &J. Joseph Melenhorst1,2,3,4 1Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA. 5Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 6Department of Cell and Developmental Biology, Epigenetics Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 7Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 8Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 9Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA. 10Present address: Department of Biology, University at Albany, State University of New York, Albany, NY, USA. 11Present address: Department of Internal Medicine and Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade

Ariyan et al.
Cancer Immunology Research
Papers
April 2018
Authors and Affiliates
Charlotte E. Ariyan1, Mary Sue Brady1, Robert H. Siegelbaum2, Jian Hu1, Danielle M. Bello1, Jamie Rand1, Charles Fisher3, Robert A. Lefkowitz4, Kathleen S. Panageas5, Melissa Pulitzer6, Marissa Vignali7, Ryan Emerson7, Christopher Tipton7, Harlan Robins7, Taha Merghoub8, Jianda Yuan8, Achim Jungbluth6, Jorge Blando9, Padmanee Sharma9, Alexander Y. Rudensky10, Jedd D. Wolchok8,10, and James P. Allison9 1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 3Department of Anesthesia, Memorial Sloan Kettering Cancer Center, New York, New York. 4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 5Department of Statistics, Memorial Sloan Kettering Cancer Center, New York, New York. 6Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 7Adaptive Biotechnology, Seattle, Washington. 8Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 9Department of Immunology, MD Anderson Cancer Center, Houston, Texas. 10Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York.

Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo

Kooreman et al.
Cell Stem Cell
Papers
April 2018
immuneAccess
Authors and Affiliates
Nigel G. Kooreman,1,2,3,4,13 Youngkyun Kim,1,2,3,7 Patricia E. de Almeida,1,2,3 Vittavat Termglinchan,1,2,3 Sebastian Diecke,8,9,10 Ning-Yi Shao,1,2,3 Tzu-Tang Wei,1,2,3 Hyoju Yi,1,2,3,7 Devaveena Dey,1,2,3 Raman Nelakanti,1,2,3 Thomas P. Brouwer,1,2,3,4 David T. Paik,1,2,3 Idit Sagiv-Barfi,5 Arnold Han,6,11,12 Paul H.A. Quax,4 Jaap F. Hamming,4 Ronald Levy,5 Mark M. Davis,6,11,12 and Joseph C. Wu1,2,3,14 1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA 2Stanford Cardiovascular Institute of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA 3Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4Department of Surgery, Leiden University Medical Center, Leiden 2333 ZA, the Netherlands 5Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA 6Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA 7Convergent Research Consortium for Immunologic Disease, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul 06591, Korea 8Max Delbru€ck Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rossle Strasse 10, 13125 Berlin, Germany 9DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany 10Berlin Institute of Health (BIH), Berlin, Germany 11Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA 12The Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

Wrangle et al.
Lancet Oncology
Papers
April 2018
Authors and Affiliates
John M Wrangle1, Vamsidhar Velcheti2, Manish R Patel3, Elizabeth Garrett-Mayer1, Elizabeth G Hill1, James G Ravenel1, Jeffrey S Miller3, Mohammad Farhad4, Kate Anderton1, Kathryn Lindsey1, Michele Taffaro-Neskey1, Carol Sherman1, Samantha Suriano1, Marzena Swiderska-Syn1, Amy Sion1, Joni Harris1, Andie R Edwards1, Julie A Rytlewski5, Catherine M Sanders5, Erik C Yusko5, Mark D Robinson6, Carsten Krieg1, William L Redmond4, Jack O Egan7, Peter R Rhode7, Emily K Jeng7, Amy D Rock7, Hing C Wong7, Mark P Rubinstein8 1Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA. 4Earle A Chiles Research Institute, Portland, OR, USA. 5Adaptive Biotechnologies, Seattle, WA, USA. 6Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland. 7Altor BioScience, Miramar, FL, USA. 8Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde et al.
New England Journal of Medicine
Papers
April 2018
Authors and Affiliates
P.M. Forde, J.E. Chaft, K.N. Smith, V. Anagnostou, T.R. Cottrell, M.D. Hellmann, M. Zahurak, S.C. Yang, D.R. Jones, S. Broderick, R.J. Battafarano, M.J. Velez, N. Rekhtman, Z. Olah, J. Naidoo, K.A. Marrone, F. Verde, H. Guo, J. Zhang, J.X. Caushi, H.Y. Chan, J.-W. Sidhom, R.B. Scharpf, J. White, E. Gabrielson, H. Wang, G.L. Rosner, V. Rusch, J.D. Wolchok, T. Merghoub, J.M. Taube, V.E. Velculescu, S.L. Topalian, J.R. Brahmer, and D.M. Pardoll From the Bloomberg-Kimmel Institute for Cancer Immunotherapy and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore (P.M.F., K.N.S., V.A., T.R.C., M.Z., S.C.Y., S.B., R.J.B., J.N., K.A.M., F.V., H.G., J.Z., J.X.C., H.Y.C., J.-W.S., R.B.S., J.W., E.G., H.W., G.L.R., J.M.T., V.E.V., S.L.T., J.R.B., D.M.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine (J.E.C., M.D.H., D.R.J., M.J.V., N.R., Z.O., V.R., J.D.W., T.M.) and the Ludwig Collaborative (J.D.W., T.M.) - all in New York; the Parker Institute for Cancer Immunotherapy, San Francisco (J.D.W., T.M.); and Swim Across America Laboratory, Charlotte, NC (J.D.W., T.M.).

Combination of ipilimumab and adoptive Cell Therapy with Tumor-infiltrating lymphocytes for Patients with Metastatic Melanoma

Mullinax et al.
Frontiers in Oncology
Papers
March 2018
Authors and Affiliates
John E. Mullinax1,2, MacLean Hall2, Sangeetha Prabhakaran3, Jeffrey Weber4, Nikhil Khushalani5, Zeynep Eroglu5, Andrew S. Brohl1,5, Joseph Markowitz2,5, Erica Royster5, Allison Richards5, Valerie Stark5, Jonathan S. Zager1,5, Linda Kelley2, Cheryl Cox2, Vernon K. Sondak5, James J. Mulé2,5, Shari Pilon-Thomas2,5 and Amod A. Sarnaik2,5 1Sarcoma Department, Moffitt Cancer Center, Tampa, FL, United States, 2Immunology Department, Moffitt Cancer Center, Tampa, FL, United States, 3Department of Surgery, University of New Mexico, Albuquerque, NM, United States, 4NYU Langone Medical Center, New York, NY, United States, 5Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, United States

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Herrera et al.
Blood
Papers
March 2018
Authors and Affiliates
Alex F. Herrera,1 Alison J. Moskowitz,2 Nancy L. Bartlett,3 Julie M. Vose,4 Radhakrishnan Ramchandren,5 Tatyana A. Feldman,6 Ann S. LaCasce,7 Stephen M. Ansell,8 Craig H. Moskowitz,2 Keenan Fenton,9 Carol Anne Ogden,9 David Taft,9 Qu Zhang,9 Kazunobu Kato,10 Mary Campbell,9 and Ranjana H. Advani11 1City of Hope National Medical Center, Duarte, CA; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO; 4University of Nebraska Medical Center, Omaha, NE; 5Karmanos Cancer Institute, Detroit, MI; 6Hackensack University Medical Center, Hackensack, NJ; 7Dana-Farber Cancer Institute, Boston, MA; 8Mayo Clinic, Rochester, MN; 9Seattle Genetics, Inc, Bothell, WA; 10Bristol-Myers Squibb, Princeton, NJ; and 11Stanford University Medical Center, Palo Alto, CA

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Usmani et al.
Experimental Hematology & Oncology
Papers
February 2018
Authors and Affiliates
Saad Z. Usmani1, Imran Khan2, Christopher Chiu3, David Foureau1, Lawrence J. Druhan1, Katherine Rigby1, Tineke Casneuf4, and A. Kate Sasser3 1Levine Cancer Institute/Carolinas Health Care System, 1021 Morehead Medical Drive, Charlotte, NC 28204 USA., 2Janssen Research & Development, LLC, Raritan, NJ USA., 3Janssen Research & Development, LLC, Spring House, PA USA., 4Janssen Research & Development, Beerse, Belgium.

RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis

Cortes et al.
Cancer Cell
Papers
February 2018
Authors and Affiliates
Jose R. Cortes,1 Alberto Ambesi-Impiombato,1 Lucile Couronné,2,3,4 S. Aidan Quinn,1 Christine S. Kim,1 Ana C. da Silva Almeida,1 Zachary West,1 Laura Belver,1 Marta Sanchez Martin,1 Laurianne Scourzic,5,6,7 Govind Bhagat,8 Olivier A. Bernard,5,6,7 Adolfo A. Ferrando,1,8,9 and Teresa Palomero1,8 1Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA, 2Department of Adult Hematology, Necker Hospital, Paris 75993, France, 3INSERM U 1163, CNRS ERL 8254, Institut Imagine, Paris 75015, France, 4Paris Descartes University, Paris 75006, France, 5Gustave Roussy, Villejuif 94805, France, 6INSERM U1170, Villejuif 94805, France, 7Universite Paris-Sud, Orsay 91400, France, 8Department of Pathology and Cell Biology, Columbia University Medical Center, 1130 St Nicholas Avenue, ICRC-401B, New York, NY 10032, USA, 9Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA

Contraction of T cell richness in lung cancer brain metastases

Mansfield et al.
Papers
Scientific Reports
February 2018
immuneAccess
Authors and Affiliates
Aaron S. Mansfield1, Hongzheng Ren2, Shari Sutor3, Vivekananda Sarangi4, Asha Nair4, Jaime Davila 4, Laura R. Elsbernd3, Julia B. Udell5, Roxana S. Dronca1, Sean Park6, Svetomir N. Markovic1, Zhifu Sun4, Kevin C. Halling2, Wendy K. Nevala3, Marie Christine Aubry2, Haidong Dong3 & Jin Jen2,7 1Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. 2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 3Department of Immunology, Mayo Clinic, Rochester, MN, USA. 4Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 5Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA. 6Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA. 7Genome Analysis Core and the Biomarker Discovery Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA